<DOC>
	<DOCNO>NCT01814059</DOCNO>
	<brief_summary>Background : - Eosinophil-associated gastrointestinal disorder ( EGID ) group related disorder affect esophagus , stomach , bowel . There two major type EGID , eosinophilic esophagitis eosinophilic gastroenteritis . They cause body 's immune system activate food allergen , damage gut wall . People EGID large number eosinophil ( type white blood cell ) gut . EGID cause difficulty swallowing , abdominal pain , nausea . - At present , drug specifically approve treat EGID . Most adults EGID receive steroid therapy manage symptom . However , long-term steroid use may cause problem body . Researchers want see low-dose sirolimus use treat EGID . Sirolimus drug use prevent rejection transplant organ . It may able keep body 's immune cell activate food allergen decrease eosinophil . Objectives : - To see low dose sirolimus safe decrease blood gut eosinophils EGID . Eligibility : - Individuals 18 65 year age EGID . - Participants must also elevate blood eosinophil count positive blood test IgE antibody food . Design : - Participants medicine EGID related symptom must stable dose 1 month screen stay dose throughout study . - Participants screen medical history physical exam , review symptom . They provide blood urine sample . They also heart lung function test . Some participant may allergy skin test . - At first study visit , participant 2 day inpatient test . They repeat test screen visit . They also full analysis esophagus , stomach , small intestine . On second day , start take sirolimus liquid orange juice water . - Participants continue take sirolimus home . They record dose symptom . They also visit provide blood sample 2 week first study visit . - At second study visit ( month first visit ) , participant repeat test screen visit . The sirolimus dose may adjust need . - Participants take sirolimus least another 28 day . Depending dose drug blood test result , participant may need take 112 day . Those take drug longer period additional study visit test . - There another study visit participant stop take drug . The last visit final follow-up visit .</brief_summary>
	<brief_title>Sirolimus Eosinophil-Associated Gastrointestinal Disorders</brief_title>
	<detailed_description>Eosinophil-Associated Gastrointestinal Disorders ( EGID ) group relate disorder characterize gastrointestinal symptom eosinophilic infiltration gastrointestinal wall . The 2 major form EGID , eosinophilic esophagitis ( EoE ) eosinophilic gastroenteritis ( EG ) , differ regard site inflammation ( esophagus vs. stomach/small bowel ) . Both EoE EG highly associate coexist allergic disease , large fraction EGID patient sensitize multiple food allergen . Existing data strongly support concept EGID food-allergen-driven , eosinophilic , inflammatory gut disease . Multiple line evidence support major role Th2 cell cytokine express ( IL-4 , IL-5 , IL-13 ) EGID pathogenesis . There presently drug label indication EGID . Most adult patient manage long-term corticosteroid therapy , raise concern toxicity . Sirolimus immunomodulator approve use prevent transplant rejection . It specifically inhibit Th2 cell proliferation vitro , suggest may activity EGID . This study phase I open-label design intend target sirolimus whole blood concentration 6 ng/mL duration 56 day . Twenty adult EGID subject 10 EoE 10 EG evidence Th2-mediated IgE sensitization peripheral blood eosinophil count ( Bullet ) 800 cells/ L recruit participate . Subjects begin sirolimus dose 1.2 mg/m2/day . Blood sirolimus level check 14- 28-day interval , dose serially adjust subject need target 6- ng/mL target trough concentration . Blood drawn visit monitor drug level safety lab .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Enteritis</mesh_term>
	<mesh_term>Eosinophilia</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>INCLUSION CRITERIA : Individuals eligible study participation meet follow criterion : 1 . Age great equal to18 year less equal 65 year time Study Visit 1 . 2 . Presence follow diagnostic criterion EGID : 1 . Subjects EoE must : 1 ) esophageal symptom ; 2 ) histologic evidence esophageal tissue infiltration eosinophils peak great equal to25 eosinophil per highpowered field ( great equal 2 month twice daily protonpump inhibitor therapy ) ; 3 ) know etiology tissue eosinophilia despite careful clinical evaluation . 2 . Subjects EG must : 1 ) gastrointestinal symptom ; 2 ) histologic evidence stomach duodenal tissue infiltration eosinophils peak great equal to35 eosinophil per highpowered field ; 3 ) know etiology tissue eosinophilia despite careful clinical evaluation . 3 . Blood AEC great equal 800 cells/microL screen visit . This screen value use calculate baseline AEC use principal secondary endpoint . 4 . Baseline laboratory value within follow range : 1 . White blood cell count great equal to3,300 cells/microL . 2 . Absolute neutrophil count great equal to1,000 cells/microL . 3 . Hemoglobin great equal to10 g/dL . 4 . Platelet count great equal to100,000 platelets/microL . 5 . Three positive allergenspecific IgE test ( skin test vitro assay ) panel 10 food aeroallergens : milk , egg , wheat , soy , shrimp , cod , corn , peanut , dust mite , cat . 6 . Subjects currently medication EGID GI symptom must stable dose 1 month prior screen willing continue dose duration study . Other medication ( e.g . hypertension , asthma , depression ) may adjust subject physician . 7 . Willingness sample store future research genetic testing . 8 . Women childbearing potential must negative serum betahCG . 9 . Agree practice abstinence effective contraception detail . Contraception : The fetal risk associate sirolimus know , preclinical animal data demonstrate risk . Subjects must agree become pregnant impregnate female , accordingly . Females childbearing potential must pregnancy test NIH visit . Because risk involve , male female subject partner must use 2 method birth control . As per sirolimus package insert , subject must continue use method 3 month stop study drug . Two method birth control may select list include : Hormonal contraception . Male female condom without spermicidal . Diaphragm cervical cap spermicidal . Intrauterine device . If pregnancy suspect occur , subject must notify study staff immediately . EXCLUSION CRITERIA : Individuals eligible participate study meet follow criterion : 1 . Are breast feed . 2 . Are HIV positive know immunodeficiency . 3 . Have use investigational agent within 6 month screen visit . 4 . Express FIP1L1PDGFR fusion gene . 5 . Have evidence preexisting proteinuria urine albumintocreatinine ratio &gt; 200 mg/g ( men ) &gt; 300 mg/g ( woman ) . 6 . Have serum creatinine estimate GFR &lt; 60 mL/min/1.73 m2 . 7 . Have chronic liver disease , include hepatitis B C. 8 . Use medication CYP3A4 Pglycoprotein ( Pgp ) inhibitor inducer activity . 9 . Are Taking ACE inhibitor medicatons 10 . Drug allergy intolerance allergy sirolimus , rapalogs , excipients preparation . 11 . Have condition , determine investigator , place patient undue risk participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 12, 2015</verification_date>
	<keyword>Sirolimus</keyword>
	<keyword>Eosinophilic Esophagitis</keyword>
	<keyword>Eosinophilic Gastroenteritis</keyword>
	<keyword>T -Cells</keyword>
	<keyword>Food Allergy</keyword>
</DOC>